File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Programmed cell death‐ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics

TitleProgrammed cell death‐ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics
Authors
KeywordsE–S grade
Hepatocellular carcinoma
Immunohistochemistry
PD-L1
TP53
Issue Date2021
PublisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGH
Citation
Journal of Gastroenterology and Hepatology, 2021, Epub 2021-03-03 How to Cite?
AbstractBackground and Aim: Programmed cell death‐ligand 1 (PD‐L1) immunohistochemistry score has been approved as the predictive biomarker for anti‐PD1/PD‐L1 therapy in several advanced malignancies. Although its predictive role remained inconclusive in hepatocellular carcinoma, ongoing study of anti‐PD1/PD‐L1 therapy showed promising results. However, less is known about the PD‐L1 immunohistochemistry score and factors correlated with it in hepatocellular carcinoma. We investigated PD‐L1 immunohistochemistry scores in a large cohort of hepatocellular carcinoma, as well as its correlation with various clinical and genomic factors. Methods: Immunohistochemistry was performed to detect the expression of PD‐L1 protein in 315 hepatocellular carcinoma tissues. All slides were independently reviewed by three senior pathologists. Next‐generation YS panel (450 genes) sequencing was performed on 309 patients. Results: Higher PD‐L1 expression as measured by combined positive score (CPS) was associated with increased Edmondson–Steiner grade (grade III vs II, P = 0.041) and TP53 mutations (P = 0.021). PD‐L1 CPS had no correlation with tumor mutational burden (Spearman's correlation coefficient 0.067). PD‐L1 CPS was not significantly associated with hepatitis B virus infection. Conclusions: Our data indicated that patients with higher Edmondson–Steiner grade (grade III) had significantly higher PD‐L1 CPS than patients with lower Edmondson–Steiner grade (grade II). Patients with TP53 mutations had significantly higher PD‐L1 expression.
Descriptioneid_2-s2.0-85102584878
Persistent Identifierhttp://hdl.handle.net/10722/289773
ISSN
2020 Impact Factor: 4.029
2015 SCImago Journal Rankings: 1.190
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorMou, H-
dc.contributor.authorYang, Q-
dc.contributor.authorYu, L-
dc.contributor.authorWang, T-
dc.contributor.authorLiu, K-
dc.contributor.authorShen, R-
dc.contributor.authorPan, X-
dc.contributor.authorDai, Y-
dc.contributor.authorWan, Q-
dc.contributor.authorZhou, F-
dc.contributor.authorQian, L-
dc.contributor.authorChen, D-
dc.contributor.authorYau, T-
dc.contributor.authorDong, X-
dc.contributor.authorWang, X-
dc.contributor.authorWang, S-
dc.date.accessioned2020-10-22T08:17:16Z-
dc.date.available2020-10-22T08:17:16Z-
dc.date.issued2021-
dc.identifier.citationJournal of Gastroenterology and Hepatology, 2021, Epub 2021-03-03-
dc.identifier.issn0815-9319-
dc.identifier.urihttp://hdl.handle.net/10722/289773-
dc.descriptioneid_2-s2.0-85102584878-
dc.description.abstractBackground and Aim: Programmed cell death‐ligand 1 (PD‐L1) immunohistochemistry score has been approved as the predictive biomarker for anti‐PD1/PD‐L1 therapy in several advanced malignancies. Although its predictive role remained inconclusive in hepatocellular carcinoma, ongoing study of anti‐PD1/PD‐L1 therapy showed promising results. However, less is known about the PD‐L1 immunohistochemistry score and factors correlated with it in hepatocellular carcinoma. We investigated PD‐L1 immunohistochemistry scores in a large cohort of hepatocellular carcinoma, as well as its correlation with various clinical and genomic factors. Methods: Immunohistochemistry was performed to detect the expression of PD‐L1 protein in 315 hepatocellular carcinoma tissues. All slides were independently reviewed by three senior pathologists. Next‐generation YS panel (450 genes) sequencing was performed on 309 patients. Results: Higher PD‐L1 expression as measured by combined positive score (CPS) was associated with increased Edmondson–Steiner grade (grade III vs II, P = 0.041) and TP53 mutations (P = 0.021). PD‐L1 CPS had no correlation with tumor mutational burden (Spearman's correlation coefficient 0.067). PD‐L1 CPS was not significantly associated with hepatitis B virus infection. Conclusions: Our data indicated that patients with higher Edmondson–Steiner grade (grade III) had significantly higher PD‐L1 CPS than patients with lower Edmondson–Steiner grade (grade II). Patients with TP53 mutations had significantly higher PD‐L1 expression.-
dc.languageeng-
dc.publisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGH-
dc.relation.ispartofJournal of Gastroenterology and Hepatology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectE–S grade-
dc.subjectHepatocellular carcinoma-
dc.subjectImmunohistochemistry-
dc.subjectPD-L1-
dc.subjectTP53-
dc.titleProgrammed cell death‐ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics-
dc.typeArticle-
dc.identifier.emailYau, T: tyaucc@hku.hk-
dc.identifier.authorityYau, T=rp01466-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1111/jgh.15475-
dc.identifier.pmid33656759-
dc.identifier.hkuros316120-
dc.identifier.volumeEpub 2021-03-03-
dc.identifier.isiWOS:000627284800001-
dc.publisher.placeAustralia-
dc.identifier.issnl0815-9319-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats